Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Livzon Pharmaceutical Group ( (HK:1513) ) has issued an announcement.
Livzon Pharmaceutical Group has called its 2025 annual general meeting for 29 May 2026 in Zhuhai, combining on-site and online voting for shareholders. The agenda covers approval of the 2025 annual report, board work report and financial accounts, reappointment of Grant Thornton as auditor for 2026, and a cash dividend distribution plan.
Shareholders will vote on reappointing Grant Thornton for 2026 with specified fees for financial statement and internal control audits. They will also consider a 2025 profit distribution proposal to pay a cash dividend of RMB14.3 per 10 shares, with no bonus shares or capitalisation of reserves, underscoring the company’s commitment to returning cash to investors.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company engaged in the research, production and sale of medicines and healthcare products. Listed in Hong Kong and Shenzhen, it focuses on prescription drugs and related medical products, serving domestic and international healthcare markets.
Average Trading Volume: 914,703
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.41B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.